Lanvis Dosage & Drug Information

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Concise Prescribing Info

Contents

Thioguanine

Indications/Uses

Acute myelogenous & lymphoblastic leukaemia.

Click to view Lanvis detailed prescribing information

Dosage/Direction for Use

Induction therapy 60-200 mg/m² daily.

Click to view Lanvis detailed prescribing information

Overdosage

View Lanvis overdosage for action to be taken in the event of an overdose.

Administration

Should be taken on an empty stomach.

Contraindications

Hypersensitivity.

Click to view Lanvis detailed prescribing information

Special Precautions

Discontinue use in patients w/ evidence of hepatic toxicity. Not recommended for maintenance therapy or similar long-term continuous therapy due to high risk of hepatic toxicity w/ vascular endothelial damage. Bone marrow suppression leading to leucopoenia & thrombocytopenia. Patients w/ inherited deficiency of thiopurine methyltransferase enzyme & NUDT15 gene variant; Lesch-Nyhan syndrome. Monitor full blood cell counts & hepatic function tests wkly during therapy. Asian patients. Limit exposure to sun- & UV light. Not to be taken by patients w/ galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Not recommended w/ live vaccines until at least 3 mth after completing chemotherapy. Combination w/ other immunosuppresive or chemotherapeutic agents. Hepatic or renal impairment. Avoid use during pregnancy & lactation.

Click to view Lanvis detailed prescribing information

Use In Pregnancy & Lactation

Click to view Lanvis detailed prescribing information

Adverse Reactions

Bone marrow failure; venoocclusive hepatic disease: hyperbilirubinaemia, hepatomegaly, increased wt, portal HTN: splenomegaly, varices oesophageal, thrombocytopenia, increased hepatic enzyme, blood alkaline phosphatase & γ-glutamyl-transferase, jaundice, portal fibrosis, nodular regenerative hyperplasia, peliosis hepatitis. Stomatitis, GI disorder; venoocclusive hepatic disease in short-term cyclical therapy; hyperuricaemia, hyperuricosuria, urate nephropathy.

Click to view Lanvis detailed prescribing information

Drug Interactions

Not recommended w/ live vaccines. Risk of myelosuppression w/ other myelotoxic substances or RT. Concomitant use w/ aminosalicylate derivatives eg, olsalazine, mesalazine or sulphasalazine.

Click to view Lanvis detailed prescribing information

Caution For Usage

For caution against possible variation of physical aspect of medicine... Click to view Lanvis detailed prescribing information

Storage

View Lanvis storage conditions for details to ensure optimal shelf-life.

Description

View Lanvis description for details of the chemical structure and excipients (inactive components).

Action

View Lanvis mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Cytotoxic Chemotherapy

ATC Classification

L01BB03 - tioguanine ; Belongs to the class of antimetabolites, purine analogues. Used in the treatment of cancer.

Regulatory Classification

Presentation/Packing

Form

Lanvis tab 40 mg

Packing/Price

25's

Lanvis

tioguanine

Manufacturer:

Aspen

Distributor:

Zuellig Pharma